ERBB2 and breast cancer: Although the NeoALLTO study showed a significant association between pCR and both DFS and OS, the OS of HER2-positive BC patients after NAC remains unclear because newly developed anti-HER2 therapies for metastatic BC may strongly affect long-term survival [38].